You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017

The prize is awarded to the companies that made the best use of the capital markets

read more 

CORPORATE

Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

read more 

CORPORATE

Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

Goal is to improve access to replacement therapies for coagulation disorders in Europe

read more 
  1. CORPORATE - 12-11-2014

    Kedrion joins the programme “ELITE for Large Corporates”

    Launched by Borsa Italiana, ELITE is targeted to companies aiming at strengthening their global leadership

    read more 
  2. EVENTS - 06-11-2014

    Kedrion Participates in International Event on Primary Immunodeficiencies

    Biennial Meeting of the European Society for Immunodeficiencies (ESID) took place in late October in Prague

    read more 
  3. CORPORATE - 17-10-2014

    Kedrion announces more factual, long-term role in Africa

    The company’s efforts try to grant African patients better access to treatments

    read more 
  4. PLASMA & BIOTHERAPIES - 16-10-2014

    Investigating inhibitor development in patients with Hemophilia A

    Lecture on state-of-the-art of the SIPPET Study presented by P.M. Mannucci, sponsored by Grifols, Kedrion and LFB

    read more 

Pages

For more information please contact: pressoffice@kedrion.com